Archivos: PDF

When discussing treatment for macular pathologies like diabetic macular edema (DME) and central serous chorioretinopathy (CSCR), injection burden is a term that often appears.

Laser photocoagulation has been used in ophthalmology for many years. During photocoagulation, a continuous wave of energy is delivered to the target tissue throughout the entire duration of the laser pulse.

Central serous chorioretinopathy (CSC) is a common posterior pole disease with a high recurrence rate and etiology. Its pathogenesis is ambiguous; however, it is characterized by the decompensation of the retinal pigment epithelium (RPE) and usually results in serous detachment of neuroretina, serous pigment epithelium detachment (PED), and RPE atrophy.

Pautas de tratamiento de Easyret: Modo multispot

Diabetic retinopathy (DR) is a major microvascular complication of diabetes. It is estimated that by 2030, nearly 200 million people will be affected by this disease. During this period, visionthreatening DR will increase from 37 million to 56 million people globally. Center-involved diabetic macular edema (CI-DME) is the most common cause of decreased visual acuity in DR patients, affecting more than 750,000 patients in the United States alone.

In this time of uncertainty, one thing is certain (at least in ophthalmology): Retinal pathologies are not going anywhere. In fact, chronic conditions like age-related macular degeneration (AMD) and diabetic retinopathy (DR) are thought to be causing more concerns during this period of worldwide lockdown and social distancing.

DME is one of the most common causes of sightthreatening retinopathy for people with diabetes, which currently affects more than 30 million people worldwide. As the prevalence of diabetes and vision diseases related to diabetes continues to rise, so does the burden it creates on health care systems.

Patients with center-involved diabetic macular edema (CI-DME) with good visual acuity (VA) represent a controversial clinical scenario in which a subthreshold laser might be a reasonable approach. We report a case series of patients with CI-DME with VA better than 20/32 who were treated with a subthreshold 577 nm (yellow) laser.

Macular laser photocoagulation (MLP) is inferior to intravitreal vascular endothelial growth factor (VEGF) inhibitors in the treatment of center-involved diabetic macular edema (DME). Ultra-widefield fluorescein angiography-guided laser photocoagulation to presumed ischemic areas of the peripheral retina or MLP do not reduce the treatment burden nor improve the visual outcomes of eyes treated with anti-VEGF drugs.

To investigate the effects of subliminal micropulse yellow laser application on the central macular thickness and best-corrected visual acuity in cystoid macular edema secondary to retinitis pigmentosa patients.